» Articles » PMID: 29496041

Double Positivity for HPV-DNA/p16 is the Biomarker with Strongest Diagnostic Accuracy and Prognostic Value for Human Papillomavirus Related Oropharyngeal Cancer Patients

Abstract

Background: The etiologic role of human papillomaviruses (HPV) in oropharyngeal cancer (OPC) is well established. Nevertheless, information on survival differences by anatomic sub-site or treatment remains scarce, and it is still unclear the HPV-relatedness definition with best diagnostic accuracy and prognostic value.

Methods: We conducted a retrospective cohort study of all patients diagnosed with a primary OPC in four Catalonian hospitals from 1990 to 2013. Formalin-fixed, paraffin-embedded cancer tissues were subjected to histopathological evaluation, DNA quality control, HPV-DNA detection, and p16/pRb/p53/Cyclin-D1 immunohistochemistry. HPV-DNA positive and a random sample of HPV-DNA negative cases were subjected to HPV-E6*I mRNA detection. Demographic, tobacco/alcohol use, clinical and follow-up data were collected. Multivariate models were used to evaluate factors associated with HPV positivity as defined by four different HPV-relatedness definitions. Proportional-hazards models were used to compare the risk of death and recurrence among HPV-related and non-related OPC.

Results: 788 patients yielded a valid HPV-DNA result. The percentage of positive cases was 10.9%, 10.2%, 8.5% and 7.4% for p16, HPV-DNA, HPV-DNA/HPV-E6*I mRNA, and HPV-DNA/p16, respectively. Being non-smoker or non-drinker was consistently associated across HPV-relatedness definitions with HPV positivity. A suggestion of survival differences between anatomic sub-sites and treatments was observed. Double positivity for HPV-DNA/p16 showed strongest diagnostic accuracy and prognostic value.

Conclusions: Double positivity for HPV-DNA/p16, a test that can be easily implemented in the clinical practice, has optimal diagnostic accuracy and prognostic value. Our results have strong clinical implications for patients' classification and handling and also suggest that not all the HPV-related OPC behave similarly.

Citing Articles

HPV Biomarkers in Oral and Blood-Derived Body Fluids in Head and Neck Cancer Patients.

Galati L, Tagliabue M, Gheit T, De Berardinis R, Maffini F, McKay-Chopin S J Med Virol. 2025; 97(3):e70278.

PMID: 40052199 PMC: 11886502. DOI: 10.1002/jmv.70278.


Prevalence of HPV Positivity and the Correlation Between P16INK4A Expression and HPV DNA Positivity in Carcinoma Oropharynx and Their Correlation With Survival Outcomes: A Retrospective Study From a Tertiary Cancer Centre in South India.

Sherief P A, Madhavan Nair L, Ravikumar R, George P, Cessal Thommachan K, Rafi M Cureus. 2025; 17(1):e77162.

PMID: 39925561 PMC: 11806965. DOI: 10.7759/cureus.77162.


Human Papillomaviruses 16 and 18 E6 Oncoprotein Detection Test in Primary Oropharyngeal Carcinomas and Metastatic Lymph Nodes: A Cross-Sectional Study.

Boscolo-Rizzo P, Polesel J, Menegaldo A, Sia E, Stellin M, Tirelli G Head Neck Pathol. 2024; 18(1):101.

PMID: 39404976 PMC: 11480278. DOI: 10.1007/s12105-024-01713-7.


Digital Spatial Profiling identifies distinct patterns of immuno-oncology-related gene expression within oropharyngeal tumours in relation to HPV and p16 status.

Brooks J, Zheng Y, Hunter K, Willcox B, Dunn J, Nankivell P Front Oncol. 2024; 14:1428741.

PMID: 39328208 PMC: 11424609. DOI: 10.3389/fonc.2024.1428741.


Significance of p16 in Site-Specific Human Papillomavirus-Positive and Negative Head and Neck Squamous Cell Carcinoma (HNSCC).

Priyatha V, Gupta H, Narsapuram P, Ahmed F, Alhussain H, Arfa A Cureus. 2024; 16(7):e63594.

PMID: 39087192 PMC: 11290380. DOI: 10.7759/cureus.63594.